Pregnancy safety study of the VLA1553 vaccine
Treatments studied
Part of Infections clinical trials.
This study follows pregnant women who received the VLA1553 vaccine (for chikungunya) to see how it affects them and their babies. It compares them to pregnant women who received a different vaccine approved during pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant at the time you join the study.
- You received the VLA1553 vaccine while pregnant or within 30 days before your last period started (for the vaccinated group).
- Or you did NOT receive the VLA1553 vaccine, but you did receive another vaccine approved for use during pregnancy (for the control group).
- You understand the study and agree to follow its rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the VLA1553 vaccine prevents chikungunya disease in parts of Brazil where the vaccine is being offered as part of a pilot program. If you live in one of those areas and have had symptoms that might be chikungunya, this study will use your health records and blood tests to check how effective the vaccine is.
This study tests a new vaccine to see if it's safe and helps protect against chikungunya virus (a mosquito-borne illness causing fever and joint pain). It's for healthy adults ages 18 to 60 who haven't recently traveled to areas with similar viruses or received certain other vaccines.
This trial tests a new treatment (PC-CHIK-V) for newborns whose mothers had chikungunya around the time of birth. The goal is to see if the treatment can prevent or reduce the infection in babies. Babies who are not treated will also be followed for comparison.
This study is for people who are eligible for the chikungunya vaccine in La Réunion. It looks at how well the vaccine works in real life, if it’s safe, and how your body responds to it.
This study looks for Chikungunya virus in the semen of men who are currently sick with the virus, to understand how long it stays there.
This study tests a vaccine for chikungunya virus in children aged 1 to 12. It aims to see if the vaccine is safe and helps the body build protection against the virus.
Hear when a new Chikungunya Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.